U.S. markets closed
  • S&P Futures

    3,845.00
    +6.00 (+0.16%)
     
  • Dow Futures

    31,565.00
    +100.00 (+0.32%)
     
  • Nasdaq Futures

    12,633.25
    -30.50 (-0.24%)
     
  • Russell 2000 Futures

    2,203.30
    +13.60 (+0.62%)
     
  • Crude Oil

    67.30
    +1.21 (+1.83%)
     
  • Gold

    1,708.50
    +10.00 (+0.59%)
     
  • Silver

    25.71
    +0.42 (+1.67%)
     
  • EUR/USD

    1.1926
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3842
    +0.0014 (+0.10%)
     
  • USD/JPY

    108.4140
    +0.0320 (+0.03%)
     
  • BTC-USD

    51,611.10
    +2,379.51 (+4.83%)
     
  • CMC Crypto 200

    1,041.03
    +97.86 (+10.38%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    29,167.08
    +302.76 (+1.05%)
     

Return On Capital Employed Overview: Inovio Pharmaceuticals

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

During Q3, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $236.18 million. Despite a 25.02% in earnings, the company posted a loss of $36.33 million. In Q2, Inovio Pharmaceuticals brought in $267.19 thousand in sales but lost $29.06 million in earnings.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Inovio Pharmaceuticals posted an ROCE of -0.11%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on INO

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Inovio Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q3 Earnings Recap

Inovio Pharmaceuticals reported Q3 earnings per share at $-0.26/share, which did not meet analyst predictions of $-0.19/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.